Clinical Trial Update: Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating autologous dendritic cells pulsed with lysed allogeneic tumor lines for Diffuse Intrinsic Pontine Glioma (DIPG).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma

Drugs mentioned

• Autologous dendritic cell vaccine pulsed with lysed allogeneic tumor lines (Dendritic cell vaccine pulsed with lysed allogeneic tumor lines)

Snippet

Sponsor: Fundació Sant Joan de Déu | Conditions: Diffuse Intrinsic Pontine Glioma | Phase 1 | Status: UNKNOWN